ORIC Pharmaceuticals Azioni (NASDAQ: ORIC)

Ultime notizie per ORIC Pharmaceuticals (NASDAQ:ORIC) Azioni

ORIC Pharmaceuticals

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals Inc

Orica Ltd

WIIM

EYEN

Eyenovia shares are trading lower after Ladenburg Thalmann downgraded the stock from Buy to Neutral. Also, HC Wainwright & Co. downgraded the stock from Buy to Neutral and lowered its price target from $12 to $2.

JMP Securities analyst David Turkaly reiterates Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Market Outperform and maintains $265 price target.

News

Price Target

Reiteration

Analyst Ratings

JMP Securities Reiterates Market Outperform on Steris, Maintains $265 Price Target

UBS analyst Daniel Major initiates coverage on Franco-Nevada (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) with a Buy rating and announces Price Target of $160.

Initiation

UBS Initiates Coverage On Franco-Nevada with Buy Rating, Announces Price Target of $160

IPOs

Trading Ideas

Damon IPO Shares Open For Trade At $4/Share

JMP Securities analyst Reni Benjamin reiterates Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Market Outperform and maintains $125 price target.

BPMC

JMP Securities Reiterates Market Outperform on Blueprint Medicines, Maintains $125 Price Target

LUXH

LuxUrban Hotels shares are trading lower after the company announced a 1-for-70 reverse stock split.

Macro Economic Events

Economics

Oil is trading higher amid escalating Russia-Ukraine tensions. Additionally, the commodity may be rising on supply issues after Norway's Johan Sverdrup oilfield was shut due to a power outage.

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $400 price target.

ALNY

HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $400 Price Target

Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) has officially announced the latest games departing Xbox Game Pass, leaving subscribers with just two weeks to <a href="https://www.benzinga.com/general/gaming">enjoy these titles. </a>
The news arrives as Age of Empires II: Definitive Edition, Spyro Reignited Trilogy, and Goat Simulator Remastered bolster the service's lineup.y loses six diverse titles, including Remnant: From the Ashes, Soccer Story, and the critically acclaimed Rollerdrome.
See Also: <a href="https://www.benzinga.com/general/gaming/24/11/41948549/xbox-handheld-a-few-years-out-says-microsoft-gaming-ceo-hints-at-cross-platform-games-new-acquisitions">Xbox Handheld &#8216;A Few Years Out,&#8217; Says Microsoft Gaming CEO; Hints At Cross-Platform Games, New Acquisitions</a>
<h3 class="wp-block-heading">Games Departing Xbox Game Pass</h3>
Here's the full roster of titles exiting Xbox Game Pass by the end of November, <a href="https://www.eurogamer.net/expansion-packs-new-game-seasons-dlcs-remakes-and-remasters-are-eligible-for-this-years-the-game-awards">according</a> to Eurogamer:
<ul>
<li>While the Iron&#8217;s Hot</li>
<li>Spirit of the North Enhanced Edition</li>
<li>Soccer Story</li>
<li>Rollerdrome</li>
<li>Conan Exiles</li>
<li>Coral Island</li>
<li>Remnant: From the Ashes</li>
</ul>
<h3 class="wp-block-heading">Xbox's Broader Strategy</h3>
Microsoft has reiterated its commitment to &#8220;bringing great games to more people on more devices,&#8221; with plans to extend its popular franchises to competing platforms like PlayStation 5 and Nintendo Switch. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/11/41985800/gta-5-joins-novembers-playstation-plus-lineup-with-other-fan-favorites">GTA 5 Joins November&#8217;s PlayStation Plus Lineup With Other Fan-Favorites</a></li>
</ul>
Image credits: Shutterstock

Gaming

General

MSFT

6 Games To Leave Xbox Game Pass By End Of Month, Including Soccer Story And Rollerdrome

DPRO

Draganfly shares are trading higher. The company announced the pricing of a $3.76 million registered direct offering.

UBS analyst Lloyd Byrne maintains Suncor Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SU#TSX">SU</a>) with a Buy and raises the price target from C$61 to C$65.

TSX:SU

UBS Maintains Buy on Suncor Energy, Raises Price Target to C$65

HC Wainwright &amp; Co. analyst Patrick Trucchio maintains ATAI Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) with a Buy and lowers the price target from $15 to $10.

ATAI

HC Wainwright & Co. Maintains Buy on ATAI Life Sciences, Lowers Price Target to $10

Petróleo Brasileiro S.A. - Petrobras, following up on the release disclosed on July 9, 2024, informs that it has signed two agreements with Yara and Araucária Nitrogenados S.A. (ANSA), a wholly-owned subsidiary of the company, in a next step towards structuring a potential partnership within fertilizers and industrial products.
The first agreement includes the commercialization by Yara of Automotive Liquid Reducing Agent (ARLA 32) produced at ANSA, which will be made using urea supplied by Yara as a raw material. This agreement will allow the resumption of domestic production of the product, which is currently imported. The industrialization process will be carried out in parallel with the activities to fully resume operations at the Araucária plant.
The second is a technical cooperation agreement for the development of joint studies of fertilizers and industrial products, as well as energy transition efforts linked to decarbonization projects and the production of renewable and low-carbon fertilizers. This scientific, technological and operational cooperation aims to achieve greater production efficiency and increase the supply of these products on the market.

Global

Earlier Reported, Petróleo Brasileiro S.A. Has Signed 2 Agreements With Yara And Araucária Nitrogenados S.A., Towards Structuring A Potential Partnership Within Fertilizers And Industrial Products

President-elect Donald Trump reportedly added more names to his list of possible picks for Treasury secretary over the weekend after Elon Musk voiced his<a href="https://www.benzinga.com/politics/24/11/42026495/musk-pushes-lutnick-for-trumps-treasury-secretary"> preference for Howard Lutnick.</a>
What Happened: Musk threw his support behind Lutnick in a post on his social media platform, X, on Saturday. The Tesla CEO and Trump-confidante also called on others to weigh in on the appointment.&nbsp;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Would be interesting to hear more people weigh in on this for <a href="https://twitter.com/realDonaldTrump?ref_src=twsrc%5Etfw">@realDonaldTrump</a> to consider feedback. My view fwiw is that Bessent is a business-as-usual choice, whereas <a href="https://twitter.com/howardlutnick?ref_src=twsrc%5Etfw">@howardlutnick</a> will actually enact change. Business-as-usual is driving America bankrupt, so we need change… <a href="https://t.co/igGLZOJ8wz">https://t.co/igGLZOJ8wz</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1857819784865362211?ref_src=twsrc%5Etfw">November 16, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Lutnick has organized fundraisers for the President-elect and is currently a co-chair of Trump's transition effort. Scott Bessent, the founder of hedge fund Key Square Group, was a principal economic advisor to Trump during his campaign and met with the President-elect at Mar-a-Lago on Friday.&nbsp;&nbsp;
Why It Matters: According to a Bloomberg<a href="https://www.bloomberg.com/news/articles/2024-11-16/musk-throws-support-to-lutnick-over-bessent-in-treasury-race?sref=TBDibEcD"> report</a>, Trump has appeared "frustrated" with the infighting. Alternatives to Lutnick and Bessent are in consideration.
Robert Lighthizer, Senator William Hagerty, former Federal Reserve governor Kevin Warsh and Marc Rowan, CEO of Apollo Global Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) are among the names being floated as alternatives, according to people familiar with the matter.&nbsp;
Trump made several unconventional picks for cabinet nominees so far, including former U.S. Representative Matt Gaetz for US <a href="https://www.benzinga.com/markets/cannabis/24/11/42036132/trump-wants-matt-gaetz-confirmed-100-so-does-the-cannabis-industry">attorney general</a> and Fox News host Pete Hegseth for defense secretary. Trump recently nominated Chris Wright, <a href="https://www.benzinga.com/24/11/42024837/trump-taps-liberty-energy-ceo-chris-wright-for-energy-secretary">oil and natural</a> gas executive, to lead the Energy Department. Wright&#8217;s attorney, William Owen Scharf, is being considered for staff secretary. 
The entire country, including Wall Street, will be watching for Trump's Treasury secretary selection as the position is responsible for formulating financial, economic and tax policies and serves as the government&#8217;s chief financial officer.&nbsp;
Investors can monitor the market's reaction to a potential Trump selection with the SPDR S&amp;P 500 ETF which tracks the performance of the S&amp;P 500 index.&nbsp;
Image: Shutterstock

Politics

ETFs

Trump Appears 'Frustrated' As Elon Musk Chimes In On Treasury Secretary, Adds More Names To List Of Potential Picks

Dave Ramsey is known today as a straight-talking personal finance expert. But before becoming a household name, Ramsey went through a <a href="https://www.benzinga.com/personal-finance/24/08/40512938/dave-ramseys-blunt-advice-your-finances-are-80-behavior-avoid-this-one-costly-mistake">financial crisis</a> that turned his life upside down. It all started when he realized how deep in debt he was – and when American Express <a href="https://x.com/DaveRamsey/status/1854926812306194616">called</a> his wife, questioning her choice to stay with a man who couldn't pay his bills. That moment sparked a transformation that changed Dave&#8217;s life and led him to help millions of others regain control of their finances.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The thing that changed my life was the nobility of my future. I looked out there into the future and I said, &quot;You know what? This is it. Never again will we borrow money. Never again is American Express going to call my house and ask my wife why she would stay with a man that… <a href="https://t.co/Y1Y2g8JhL2">pic.twitter.com/Y1Y2g8JhL2</a>
&mdash; Dave Ramsey (@DaveRamsey) <a href="https://twitter.com/DaveRamsey/status/1854926812306194616?ref_src=twsrc%5Etfw">November 8, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/red-ventures"> The percentage may shock you</a>.</li>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
<li><a href="https://www.benzinga.com/money/cd-valet-growth">CD Popularity Soars: Over 50 Million Americans Embrace Safe Savings with 5–10% Annual Growth</a></li>
</ul>
In the late 1980s, Ramsey was flying high. By age 28, he had built up a $4 million real estate portfolio and was well on his way to what he thought was lasting wealth. But things came crashing down fast. Changes in banking laws led to his loans being called in and Ramsey suddenly <a href="https://www.benzinga.com/startups/24/10/41496567/i-splatted-it-hurt-says-dave-ramsey-referring-to-the-sudden-call-on-his-1-2-million-loans-that-turne">needed to repay $1.2 million</a>. He was forced into bankruptcy with no way to liquidate his properties quickly enough.
That was a tough pill to swallow. Ramsey recalls, &#8220;I splatted. It hurt.&#8221; The financial crash didn't just wipe out his wealth; it made life at home tense and uncertain. To make things worse, creditors were relentless. Ramsey vividly remembers when an American Express representative called his wife, Sharon, asking why she'd "stay with a man that won't pay his bills." "I was a very mad redneck,&#8221; Ramsey admits and that was the moment he knew things had to change.
Trending: Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a>
Ramsey made a decision: No more debt. Ever again. He vowed to be "the last Ramsey in this branch of the family tree in debt." He <a href="https://www.benzinga.com/personal-finance/24/10/41258919/dave-ramsey-tells-mark-cuban-75-of-the-worlds-richest-say-do-this-to-build-wealth-listen-to-them">canceled all his credit cards</a>, swore off borrowing money and resolved to teach his children – and anyone else who would listen – how to build wealth without relying on debt. It wasn&#8217;t just about building wealth but about breaking the cycle and starting a new chapter.
See Also: This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.
Ramsey and Sharon lived on a strict budget, drove an old car and made sacrifices to make ends meet. &#8220;It was so bad that I was highly motivated to get out of that car as fast as I could,&#8221; Ramsey shared. But those sacrifices paid off.&nbsp;
They gradually climbed out of the hole and as they did, people began noticing Ramsey&#8217;s changes. Friends encouraged him to share his story and before long, he spoke to church groups and hosted a small radio show. This began his life's mission: helping others escape the debt trap.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/62-years-old-with-1-mil-saved">I&#8217;m 62 Years Old And Have $1.2 Million Saved. Is This Enough to Retire Stress-Free?</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>

Personal Finance

Dave Ramsey Recalls The Day American Express Called His Wife, Asking Why Stay 'With A Man That Won't Pay His Bills.' Here's What He Did Next

In the current market session, Dow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) price is at $44.20, after a 0.36% spike. However, over the past month, the stock decreased by 15.14%, and in the past year, by 14.59%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1731951908_0.png" alt="Past Year Chart" />

<h3>Dow P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Dow has a lower P/E than the aggregate P/E of 35.65 of the Chemicals industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1731951908_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

P/E Ratio Insights for Dow

UBS analyst Josh Silverstein maintains APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) with a Neutral and lowers the price target from $29 to $28.

UBS Maintains Neutral on APA, Lowers Price Target to $28

HC Wainwright &amp; Co. analyst Edward White reiterates Larimar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>) with a Buy and maintains $15 price target.

Larimar Therapeutics, Inc. - Common Stock

LRMR

HC Wainwright & Co. Reiterates Buy on Larimar Therapeutics, Maintains $15 Price Target

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Cabaletta Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) with a Buy and maintains $25 price target.

CABA

HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $25 Price Target

Management

Brazil's Petrobras Says Its Management Proposed To Board A $111B 2025-2029 Strategic Plan; Board To Discuss Strategic Plan Proposed By Management On Nov. 21

Wedbush analyst David Nierengarten maintained a Buy rating on Oric Pharmaceuticals (ORIC – Research Report) today and set a price target of $20.00....

Oric Pharmaceuticals (ORIC) Gets a Buy from Wedbush

Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on Oric Pharmaceuticals (ORIC – Research Report) and keeping the price target at ...

Buy Rating Affirmed for Oric Pharmaceuticals Amid Promising Collaborations and Strategic Clinical Advances

ORIC Pharmaceuticals (ORIC) announced the company presented a poster highlighting certain best-in-class properties of ORIC-114, a brain penetrant, ...

Oric Pharmaceuticals presents data on ORIC-114

Wells Fargo initiated coverage of Oric Pharmaceuticals (ORIC) with an Overweight rating and $20 price target The firm likes the setup for the share...

Wells starts Oric Pharmaceuticals with Overweight into 'de-risking catalysts'

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Wingstop upgraded, Estee Lauder downgraded: Wall Street's top analyst calls

"We are encouraged by the growing evidence supporting the potential best-in-class profiles of ORIC-114 and ORIC-944, and we continue to steadily ad...

Oric Pharmaceuticals reports Q3 EPS (49c), consensus (48c)

Oric Pharmaceuticals (ORIC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Soumit Roy from...

Promising Advancements in Cancer Treatment: Buy Rating for ORIC Pharmaceuticals

ORIC Pharmaceuticals GAAP EPS of -$0.49 in-line

In a report released today, Bradley Canino from Stifel Nicolaus maintained a Buy rating on Oric Pharmaceuticals (ORIC – Research Report), with a pr...

Stifel Nicolaus Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC)

Oric Pharmaceuticals Inc ( ($ORIC) ) has released its Q3 earnings. Here is a breakdown of the information Oric Pharmaceuticals Inc presented to its...

Oric Pharmaceuticals Reports Strong Financial Growth and Clinical Progress

BRZE

ENLC

NVDA

ORIC

SMCI

TERN

VNDA

WING

Press Releases

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

OpenBench and ORIC Pharmaceuticals Launch Success-Driven Discovery Collaboration

ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Candid Therapeutics Appoints Highly Accomplished Industry Leaders Angie You, Ph.D. and Dan Puckett to it's Board of Directors

Health Care

ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Comments

ORIC Pharmaceuticals

Notizie

Ultime notizie per ORIC Pharmaceuticals (NASDAQ:ORIC) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO